secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040950
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology Q2 2023: Net loss $32.2M; cash $512.1M; pipeline advances with Phase 3 start
--------------------------------------------------------------------------------

- Cash and investments $512.1M as of June 30, 2023; expected runway into 2026.
- Net loss $32.2M in Q2 2023 vs $58.1M in Q1 2023; R&D expenses decreased due to one-time $25M upfront in Q1.
- Phase 3 REZILIENT-3 study of zipalertinib in EGFR exon20 NSCLC first-line initiated in August 2023.
- CLN-619 monotherapy expansion cohorts in endometrial and cervical cancers initiated; first patient dosed in Phase 1 CLN-978 for R/R B-NHL.
- IND cleared for CLN-617; Phase 1 study expected to start in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/0000950170-23-040950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/cgem-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer